07/09/2024
"A strong vision ignites the passion and commitment needed to lead others towards greatness." Ad so it will be with the Pulmonary Fibrosis Foundation's new CEO!
The Board of Directors of the Pulmonary Fibrosis Foundation (PFF), the nation’s leading pulmonary fibrosis (PF) research, education and advocacy organization, today announced the appointment of Scott Staszak to President and Chief Executive Officer, effective immediately. Staszak was appointed in the role of Interim CEO earlier this year.
“On behalf of the PFF Board, I am pleased that Scott has agreed to serve as the PFF’s next President and CEO,” said David McNinch, Chairman of the PFF Board of Directors. “From the development of the PFF’s Care Center Network to the expansion of PF support groups nationwide, Scott has been integral to the growth and success of the Foundation since he joined the organization 14 years ago. I have known and worked with Scott for over a decade, and he has the experience, capabilities and vision to lead the PFF well into the future.”
“I am honored and grateful for the opportunity to assume the role of President and CEO for the PFF,” said Staszak. “We have a tremendous responsibility to patients, their family members and loved ones, and I look forward to collaborating with all members of the community to provide better solutions for everyone impacted by pulmonary fibrosis.”
Staszak was previously the PFF’s Chief Operating Officer and directed the implementation of the strategic plan and managed education, research, finance, development, human resources and IT operations. He has been instrumental in launching the PFF Registry, PFF Scholars, Clinical Trial Finder and numerous other initiatives.
In addition to his professional experience with the Foundation, Staszak has a personal connection to pulmonary fibrosis. His mother suffered from idiopathic pulmonary fibrosis and succumbed to the disease in 2015.
PF is a progressive, debilitating disease that causes scarring in the lungs and is part of a larger group of more than 200 interstitial lung diseases (ILDs), which are characterized by inflammation and/or scarring in the lungs. PF and ILDs impact over 250,000 Americans, and there are approximately 50,000 individuals who are newly diagnosed each year.